Company intelligence / Profile preview
Leyden Labs
Leiden, Netherlandsleydenlabs.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Leyden Labs is advancing intranasal antibody programs, including PanFlu candidate CR9114 which has entered Phase 1 clinical trials for influenza prophylaxis. The company has published data confirming the potential of its intranasal antibody approach.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Monoclonal antibodiesBispecific antibodiesIntranasal antibody formulations
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
Beyond the preview
Go deeper on Leyden Labs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leyden Labs.